Compare GSBC & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GSBC | IOVA |
|---|---|---|
| Founded | 1923 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 870.9M | 1.7B |
| IPO Year | 1996 | 2008 |
| Metric | GSBC | IOVA |
|---|---|---|
| Price | $79.55 | $10.05 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $65.00 | $9.00 |
| AVG Volume (30 Days) | 70.2K | ★ 13.0M |
| Earning Date | 04-15-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.54% | N/A |
| EPS Growth | ★ 17.68 | 14.84 |
| EPS | ★ 2.99 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $47.74 |
| Revenue Next Year | $2.56 | $40.31 |
| P/E Ratio | $26.81 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $53.76 | $1.76 |
| 52 Week High | $82.91 | $9.36 |
| Indicator | GSBC | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 54.43 | 70.70 |
| Support Level | $76.29 | $3.82 |
| Resistance Level | $82.19 | N/A |
| Average True Range (ATR) | 1.42 | 0.42 |
| MACD | 0.11 | -0.01 |
| Stochastic Oscillator | 70.26 | 86.11 |
Great Southern Bancorp Inc is a bank holding company. Through its subsidiaries, the company mainly offers a variety of banking and banking-related services, such as accepting deposits, granting loans and advances, offering mobile banking services, issuing debit and credit cards, safe deposit boxes, ATM facilities, and other related products and services. These services are offered through full-service retail banking offices and loan production offices located across different states in the U.S., including Missouri, Iowa, Kansas, Minnesota, Nebraska, Arkansas, and others.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.